Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

NextCure’s NC318 data shines light on SIGLEC15 as next hot IO target

Erin McCallister, Senior Editor
November 5, 2019 10:38 PM UTC
Updated on Nov 6, 2019 at 1:19 AM UTC

Phase I data from a cohort of NSCLC patients treated with NextCure’s NC318 suggest the SIGLEC15-targeted mAb could be the next immunotherapy to rival the single agent efficacy of PD-1 and PD-L1 inhibitors.

The data drove shares of NextCure Inc. (NASDAQ:NXTC) up $65.79 (248%) to $92.22, giving the company a market cap of $2.1 billion. The stock is now trading at six times the offering price from the company’s May IPO...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Nextcure Inc.